Search - tctmd.com

Displaying 21 - 35 of 35

Sort: Relevancy | Date

News Daily News

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

Yael L. Maxwell

October 26, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Conference News ACC 2015

MATRIX Provides Support for Radial Access, Mixed Results for Bivalirudin

March 17, 2015

News Conference News ACC 2014

EUROMAX: Bivalirudin May Hold Key to Solving Problem of Early ST After Primary PCI

March 29, 2014

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

March 25, 2012

News Daily News

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

March 06, 2012

News Daily News

Sponsors Pull the Plug on TRIGGER-PCI

March 18, 2011

Optimizing the Duration of DAPT following PCI

CME

Optimizing the Duration of DAPT following PCI

PLX Pharma - Aspirin for the Interventionalist: More Than Meets the Eye

CME

Aspirin for the Interventionalist: More Than Meets the Eye

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Everyday Antiplatelet Decisions: Making the Right Choices

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

CME

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.